286 related articles for article (PubMed ID: 9887328)
1. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease.
Hackam AS; Singaraja R; Zhang T; Gan L; Hayden MR
Hum Mol Genet; 1999 Jan; 8(1):25-33. PubMed ID: 9887328
[TBL] [Abstract][Full Text] [Related]
2. Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.
Hackam AS; Hodgson JG; Singaraja R; Zhang T; Gan L; Gutekunst CA; Hersch SM; Hayden MR
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1047-55. PubMed ID: 10434304
[TBL] [Abstract][Full Text] [Related]
3. A cellular model that recapitulates major pathogenic steps of Huntington's disease.
Lunkes A; Mandel JL
Hum Mol Genet; 1998 Sep; 7(9):1355-61. PubMed ID: 9700187
[TBL] [Abstract][Full Text] [Related]
4. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.
Cooper JK; Schilling G; Peters MF; Herring WJ; Sharp AH; Kaminsky Z; Masone J; Khan FA; Delanoy M; Borchelt DR; Dawson VL; Dawson TM; Ross CA
Hum Mol Genet; 1998 May; 7(5):783-90. PubMed ID: 9536081
[TBL] [Abstract][Full Text] [Related]
5. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions.
Lunkes A; Lindenberg KS; Ben-Haïem L; Weber C; Devys D; Landwehrmeyer GB; Mandel JL; Trottier Y
Mol Cell; 2002 Aug; 10(2):259-69. PubMed ID: 12191472
[TBL] [Abstract][Full Text] [Related]
6. Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract.
Hazeki N; Nakamura K; Goto J; Kanazawa I
Biochem Biophys Res Commun; 1999 Mar; 256(2):361-6. PubMed ID: 10079189
[TBL] [Abstract][Full Text] [Related]
7. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
8. Huntingtin contains a highly conserved nuclear export signal.
Xia J; Lee DH; Taylor J; Vandelft M; Truant R
Hum Mol Genet; 2003 Jun; 12(12):1393-403. PubMed ID: 12783847
[TBL] [Abstract][Full Text] [Related]
9. Polyglutamine pathogenesis.
Ross CA; Wood JD; Schilling G; Peters MF; Nucifora FC; Cooper JK; Sharp AH; Margolis RL; Borchelt DR
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1005-11. PubMed ID: 10434299
[TBL] [Abstract][Full Text] [Related]
10. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats.
Li SH; Li XJ
Hum Mol Genet; 1998 May; 7(5):777-82. PubMed ID: 9536080
[TBL] [Abstract][Full Text] [Related]
11. Huntingtin fragments that aggregate go their separate ways.
DiFiglia M
Mol Cell; 2002 Aug; 10(2):224-5. PubMed ID: 12191468
[TBL] [Abstract][Full Text] [Related]
12. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
Truant R; Atwal RS; Burtnik A
Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
[TBL] [Abstract][Full Text] [Related]
13. Nuclear targeting of mutant Huntingtin increases toxicity.
Peters MF; Nucifora FC; Kushi J; Seaman HC; Cooper JK; Herring WJ; Dawson VL; Dawson TM; Ross CA
Mol Cell Neurosci; 1999 Aug; 14(2):121-8. PubMed ID: 10479410
[TBL] [Abstract][Full Text] [Related]
14. Protein aggregation in Huntington's disease.
Hoffner G; Djian P
Biochimie; 2002 Apr; 84(4):273-8. PubMed ID: 12106904
[TBL] [Abstract][Full Text] [Related]
15. Complex interplay between the length and composition of the huntingtin-derived peptides modulates the intracellular behavior of the N-terminal fragments of mutant huntingtin.
Milewski M; Gawliński P; Bąk D; Matysiak A; Bal J
Eur J Cell Biol; 2015 May; 94(5):179-89. PubMed ID: 25773959
[TBL] [Abstract][Full Text] [Related]
16. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice.
Schilling G; Savonenko AV; Klevytska A; Morton JL; Tucker SM; Poirier M; Gale A; Chan N; Gonzales V; Slunt HH; Coonfield ML; Jenkins NA; Copeland NG; Ross CA; Borchelt DR
Hum Mol Genet; 2004 Aug; 13(15):1599-610. PubMed ID: 15190011
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a recruitment and sequestration mechanism in Huntington's disease.
Preisinger E; Jordan BM; Kazantsev A; Housman D
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1029-34. PubMed ID: 10434302
[TBL] [Abstract][Full Text] [Related]
18. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
Jana NR; Zemskov EA; Wang Gh ; Nukina N
Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
[TBL] [Abstract][Full Text] [Related]
19. Are there multiple pathways in the pathogenesis of Huntington's disease?
Aronin N; Kim M; Laforet G; DiFiglia M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):995-1003. PubMed ID: 10434298
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus.
Gafni J; Hermel E; Young JE; Wellington CL; Hayden MR; Ellerby LM
J Biol Chem; 2004 May; 279(19):20211-20. PubMed ID: 14981075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
